Evidence map›Paper›PMID 42737533›Full record

ArticleInternational journal of molecular sciences2026

Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction.

Takuro Saito, Mitsuru Saito, Ryohei Yamamoto, Ryuichiro Sagehashi, Yu Aoyama, Mizuki Mori, Chika Kajiwara, Kengo Furihata, Hideaki Kagaya, Hironobu Yagishita and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takuro SaitoDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0009-0002-7322-4630
Mitsuru SaitoDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Ryohei YamamotoDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Ryuichiro SagehashiDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Yu AoyamaDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Mizuki MoriDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Chika KajiwaraDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Kengo FurihataDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
Hideaki KagayaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
Hironobu YagishitaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
Nobuhiro FujiyamaCenter for Kidney Disease and Transplantation, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0000-0001-9411-2254
Soki KashimaDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0000-0003-4536-3449
Kazuyuki NumakuraDepartment of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa 078-8510, Japan.ORCID 0000-0002-5899-1738
Shintaro NaritaDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0000-0003-2988-1860
Masafumi KikuchiDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0000-0003-2148-6129
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0000-0001-7120-2425
Tomonori HabuchiDepartment of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.

Funding

Japan Society for the Promotion of Science 24K12456
6 · The paper itself

Abstract

Chronic allograft dysfunction, driven by interstitial fibrosis and tubular atrophy, remains a major cause of long-term renal allograft loss. Everolimus (EVR), a mammalian target of rapamycin (mTOR) inhibitor, may reduce fibrosis through antifibrotic effects and calcineurin inhibitor minimization. This study aimed to evaluate the impact of EVR-involving immunosuppression on renal allograft fibrosis and to identify predictors of fibrotic progression. A total of 104 living-donor kidney transplant recipients transplanted between 2011 and 2017 were retrospectively analyzed (EVR,

Indexed as

EverolimusImmunosuppressive AgentsKidneyKidney DiseasesKidney TransplantationSignal TransductionTOR Serine-Threonine KinasesAdaptor Proteins, Signal TransducingCell Cycle ProteinsFemaleFibrosisGraft RejectionGraft SurvivalHumansImmunosuppression TherapyMaleAdaptor Proteins, Signal TransducingCell Cycle ProteinsEIF4EBP1 protein, humanEverolimusImmunosuppressive AgentsMTOR protein, humanTOR Serine-Threonine Kinasesinterstitial fibrosiskidney transplant outcomesliving kidney transplantationmammalian target of rapamycin inhibitormammalian target of rapamycin-related protein

Identifiers

PMID42737533
PMCPMC13566268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.